Connor, Clark & Lunn Investment Management (CC&L)
LRMR icon

Connor, Clark & Lunn Investment Management (CC&L)’s Larimar Therapeutics LRMR Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$182K Sell
59,788
-9,299
-13% -$36.9K ﹤0.01% 1574
2026
Q1 		$311K Buy
69,087
+48,017
+228% +$192K ﹤0.01% 1414
2025
Q4 		$80.3K Buy
+21,070
New +$81.9K ﹤0.01% 1490
2024
Q4 		– Sell
-23,521
Closed -$154K – 1531
2024
Q3 		$154K Sell
23,521
-311
-1% -$2.5K ﹤0.01% 1347
2024
Q2 		$173K Sell
23,832
-34,284
-59% -$263K ﹤0.01% 1275
2024
Q1 		$441K Buy
+58,116
New +$453K ﹤0.01% 1149
2023
Q4 		– Sell
-21,835
Closed -$86.2K – 1486
2023
Q3 		$86.2K Sell
21,835
-26,239
-55% -$99.2K ﹤0.01% 1303
2023
Q2 		$150K Buy
48,074
+6,227
+15% +$25.4K ﹤0.01% 1222
2023
Q1 		$190K Buy
41,847
+4,362
+12% +$22.8K ﹤0.01% 1105
2022
Q4 		$155K Buy
37,485
+24,420
+187% +$83.3K ﹤0.01% 1082
2022
Q3 		$42K Buy
+13,065
New +$32.7K ﹤0.01% 1069
2019
Q3 		– Sell
-9,889
Closed -$141K – 1031
2019
Q2 		$141K Sell
9,889
-10,952
-53% -$292K ﹤0.01% 934
2019
Q1 		$685K Buy
20,841
+296
+1% +$15.2K ﹤0.01% 608
2018
Q4 		$1.22M Buy
20,545
+1,385
+7% +$137K 0.01% 511
2018
Q3 		$2.69M Buy
19,160
+3,158
+20% +$383K 0.02% 397
2018
Q2 		$1.96M Buy
16,002
+1,233
+8% +$105K 0.01% 480
2018
Q1 		$1.32M Buy
14,769
+959
+7% +$81.3K 0.01% 448
2017
Q4 		$766K Hold
13,810
– – ﹤0.01% 558
2017
Q3 		$583K Hold
13,810
– – ﹤0.01% 614
2017
Q2 		$582K Buy
13,810
+2,091
+18% +$107K ﹤0.01% 577
2017
Q1 		$655K Buy
11,719
+2,244
+24% +$111K ﹤0.01% 578
2016
Q4 		$362K Buy
9,475
+1,031
+12% +$41.8K ﹤0.01% 677
2016
Q3 		$335K Buy
8,444
+1,992
+31% +$90.5K ﹤0.01% 651
2016
Q2 		$464K Buy
6,452
+1,442
+29% +$114K ﹤0.01% 594
2016
Q1 		$402K Buy
5,010
+608
+14% +$48K ﹤0.01% 601
2015
Q4 		$332K Buy
4,402
+3,510
+393% +$564K ﹤0.01% 610
2015
Q3 		$342K Buy
+892
New +$402K ﹤0.01% 579

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s LRMR Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Larimar Therapeutics (LRMR) stake by 13% in Q2 2026, selling an estimated $36.9K and leaving 59,788 shares worth $182K. The position accounts for ﹤0.01% of the portfolio, ranked #1574.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in LRMR in Q3 2015 and has held it in 27 quarters since. The position peaked at $2.69M in Q3 2018. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 59,788 shares of Larimar Therapeutics worth $182K as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 9,299 Larimar Therapeutics shares in Q2 2026, an estimated $36.9K.
  • Larimar Therapeutics made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1574 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Larimar Therapeutics in Q3 2015 and has held it in 27 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Larimar Therapeutics position peaked at $2.69M in Q3 2018.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.